Publications by authors named "S Bascı"
: The Wilms' tumor gene 1 (WT1) plays a critical role in cell development and the regulation of essential genes involved in cell growth and metabolism. In the context of hematopoietic tumors, including acute myeloid leukemia (AML), WT1 has been identified as a potential marker for measurable residual disease (MRD) assessment. Relapse after allogeneic hematopoietic stem cell transplantation (allo-SCT) remains a significant challenge in AML treatment, highlighting the importance of MRD monitoring for risk stratification and treatment decisions.
View Article and Find Full Text PDFIs neutropenic fever an obstacle to effective stem cell harvesting?
Asian J Transfus Sci
September 2022
Article Synopsis
- Autologous stem cell transplantation (ASCT) is an effective treatment for hematologic cancers, but some patients can't collect enough stem cells with just G-CSF, leading to the use of chemomobilization.
- In a study of 183 lymphoma and myeloma patients, 43 experienced febrile neutropenia (FN), showing lower preapheresis blood counts and slower platelet and neutrophil recovery post-transplant.
- Despite the challenges posed by FN, sufficient harvesting of CD34+ stem cells remains possible, indicating the need for prompt treatment of FN and possibly more apheresis sessions.
Introduction: Cyclosporine-A (CsA) and post transplantation cyclophosphamide (PTCy) are common agents used for graft versus host disease (GVHD) prophylaxis in Haploidentical hematopoietic cell transplantation (haplo-HCT). However, the impact of CsA cessation timing in the posttransplant setting on clinical outcomes is uncertain. We aimed to investigate the impact of a novel approach that integrated early CsA cessation with PTCy utilization.
View Article and Find Full Text PDFArticle Synopsis
- This study investigates the feasibility and success factors of collecting peripheral blood stem cells (PBSC) from healthy donors on the 4th day of mobilization, instead of the usual 5th day, using G-CSF.
- Data from 141 healthy donors showed that 81.6% had adequate mobilization, with higher CD34+ cell counts linked to successful early collection.
- The researchers developed a predictive model for clinicians considering early collection, highlighting the importance of donor/recipient weight ratio and CD34+ cell count to maximize success rates.
A multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least ≥ two lines of therapy. Patients' treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.
View Article and Find Full Text PDF